Aktis Oncology, Inc. SEC filings AKTS
Aktis Oncology, Inc. has 68 filings in SEC EDGAR's recent list, going back to Oct 2, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 24, 2026 | Sep 23, 2026 |
| 144 | Notice of proposed sale | Sep 23, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 4 | Insider transaction | Jul 21, 2026 | Jul 20, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 17, 2026 |
| 144 | Notice of proposed sale | Jul 20, 2026 | — |
| 144 | Notice of proposed sale | Jul 17, 2026 | — |
| 4 | Insider transaction | Jul 10, 2026 | Jul 8, 2026 |
| 4 | Insider transaction | Jul 10, 2026 | Jul 8, 2026 |
| 144 | Notice of proposed sale | Jul 8, 2026 | — |
| 144 | Notice of proposed sale | Jul 8, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 14, 2026 | — |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 4 | Insider transaction | Apr 16, 2026 | Apr 15, 2026 |
| 3 | Initial insider ownership | Apr 16, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 16, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 20, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 20, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 15, 2026 | — |
| 3 | Initial insider ownership | Jan 15, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 14, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 14, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 14, 2026 | Jan 12, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Jan 14, 2026 | — |
| 4 | Insider transaction | Jan 12, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 12, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 12, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Jan 12, 2026 | Jan 12, 2026 |
| S-8 | Employee stock plan registration | Jan 12, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 12, 2026 | Jan 12, 2026 |
| 424B4 | Prospectus | Jan 9, 2026 | — |
| EFFECT | Filing | Jan 8, 2026 | — |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| 3 | Initial insider ownership | Jan 8, 2026 | Jan 8, 2026 |
| CERT | Filing | Jan 8, 2026 | — |
| 8-A12B | Filing | Jan 7, 2026 | — |
| S-1/A | Amended registration statement | Jan 7, 2026 | — |
| CORRESP | Letter to the SEC | Jan 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 6, 2026 | — |
| S-1/A | Amended registration statement | Jan 5, 2026 | — |
| S-1 | Registration statement | Dec 19, 2025 | — |
| DRS/A | Filing | Nov 14, 2025 | — |
| DRS/A | Filing | May 22, 2025 | — |
| DRSLTR | Filing | Dec 13, 2024 | — |
| DRS/A | Filing | Dec 13, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| DRSLTR | Filing | Nov 22, 2024 | — |
| DRS/A | Filing | Nov 22, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| DRS | Filing | Oct 11, 2024 | — |
| D | Filing | Oct 2, 2024 | — |
Showing 68 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2035832
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.